These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28437278)

  • 1. Pharmacodynamic and -kinetic Behavior of Low-, Intermediate-, and High-Dose Landiolol During Long-Term Infusion in Whites.
    Krumpl G; Ulč I; Trebs M; Kadlecová P; Hodisch J; Maurer G; Husch B
    J Cardiovasc Pharmacol; 2017 Jul; 70(1):42-51. PubMed ID: 28437278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of Low-, Intermediate-, and High-Dose Landiolol and Esmolol During Long-Term Infusion in Healthy Whites.
    Krumpl G; Ulč I; Trebs M; Kadlecová P; Hodisch J; Maurer G; Husch B
    J Cardiovasc Pharmacol; 2018 Mar; 71(3):137-146. PubMed ID: 29112591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.
    Krumpl G; Ulc I; Trebs M; Kadlecová P; Hodisch J
    Eur J Clin Pharmacol; 2017 Apr; 73(4):417-428. PubMed ID: 28091703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults.
    Krumpl G; Ulč I; Trebs M; Kadlecová P; Hodisch J
    BMC Pharmacol Toxicol; 2020 Nov; 21(1):82. PubMed ID: 33239108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group.
    Krumpl G; Ulc I; Trebs M; Kadlecová P; Hodisch J
    Eur J Pharm Sci; 2016 Sep; 92():64-73. PubMed ID: 27373605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, pharmacodynamics, and safety of landiolol hydrochloride in healthy Chinese subjects.
    Wang M; Zhang Q; Hua W; Zhou W; Huang M; Wang H
    Drug Res (Stuttg); 2014 Mar; 64(3):141-5. PubMed ID: 24002929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra short-acting beta1-selective blocker, in a dose escalation regimen in healthy male volunteers.
    Murakami M; Furuie H; Matsuguma K; Wanibuchi A; Kikawa S; Irie S
    Drug Metab Pharmacokinet; 2005 Oct; 20(5):337-44. PubMed ID: 16272751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra-short-acting beta1-blocker.
    Takahata T; Yasui-Furukori N; Sakamoto J; Suto K; Suto T; Tateishi T; Munakata A
    Drugs R D; 2005; 6(6):385-94. PubMed ID: 16274261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in gynecologic patients.
    Kunisawa T; Yamagishi A; Suno M; Nakade S; Higashi R; Kurosawa A; Sugawara A; Matsubara K; Iwasaki H
    J Anesth; 2015 Apr; 29(2):198-205. PubMed ID: 25186494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous administration of landiolol reduced QT dispersion in postoperative patients.
    Suzuki K; Numaguchi A; Adachi YU; Obata Y; Hatano T; Ejima T; Sato S; Matsuda N
    J Clin Anesth; 2014 Sep; 26(6):438-42. PubMed ID: 25204509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study.
    Xiao J; He P; Zou Q; Zhao Y; Xue Z; Deng X; Li S; Guo Q; Tao G; Yang T; Lang Z; He J; Wang X
    J Clin Anesth; 2015 Mar; 27(2):120-8. PubMed ID: 25434501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective Dose of Landiolol, an Ultra-Short-Acting β-Blocker, to Decrease Heart Rate During On-Pump, Beating Coronary Artery Bypass Grafting.
    Kawashima S; Kurita T; Morita K; Nakajima Y
    J Cardiothorac Vasc Anesth; 2019 Aug; 33(8):2195-2200. PubMed ID: 30902552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure.
    Adachi T; Sato A; Baba M; Hiraya D; Hasegawa T; Kuroki K; Hoshi T; Aonuma K
    Heart Vessels; 2014 Jul; 29(4):464-9. PubMed ID: 23801459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation/Atrial Flutter in Caucasian Patients.
    Stix G; Wolzt M; Domanovits H; Kadlecová P; Husch B; Trebs M; Hodisch J; Unger M; Krumpl G
    Circ J; 2019 Dec; 84(1):33-42. PubMed ID: 31813897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bolus administration of landiolol, a short-acting, selective beta1-blocker, to treat tachycardia during anesthesia: a dose-dependent study.
    Harasawa R; Hayashi Y; Iwasaki M; Kamibayashi T; Mashimo T
    J Cardiothorac Vasc Anesth; 2006 Dec; 20(6):793-5. PubMed ID: 17138082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute hemodynamic effects of landiolol, an ultra-short-acting beta-blocker, in patients with acute coronary syndrome: preliminary study.
    Hoshi T; Sato A; Nishina H; Kakefuda Y; Wang Z; Noguchi Y; Aonuma K
    J Cardiol; 2012 Oct; 60(4):252-6. PubMed ID: 22835733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness and safety of landiolol hydrochloride, an ultra-short-acting β1-blocker, in postoperative patients with supraventricular tachyarrhythmias: a multicenter, randomized, double-blind, placebo-controlled study.
    Taenaka N; Kikawa S
    Am J Cardiovasc Drugs; 2013 Oct; 13(5):353-64. PubMed ID: 23818039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age and sex-related differences in dose-dependent hemodynamic response to landiolol hydrochloride during general anesthesia.
    Mizuno J; Yoshiya I; Yokoyama T; Yamada Y; Arita H; Hanaoka K
    Eur J Clin Pharmacol; 2007 Mar; 63(3):243-52. PubMed ID: 17211618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of low-dose landiolol, an ultrashort-acting beta-blocker, on postoperative atrial fibrillation after CABG surgery.
    Fujiwara H; Sakurai M; Namai A; Kawamura T
    Gen Thorac Cardiovasc Surg; 2009 Mar; 57(3):132-7. PubMed ID: 19280308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β1-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease.
    Jinzaki M; Hirano M; Hara K; Suzuki T; Yamashina A; Ikari Y; Iino M; Yamaguchi T; Kuribayashi S
    Int J Cardiovasc Imaging; 2013 Jun; 29 Suppl 1(Suppl 1):7-20. PubMed ID: 23784548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.